Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6619–6625 | Cite as

Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer

  • Zehua Bian
  • Yuyang Feng
  • Yao Xue
  • Yaling Hu
  • Qifeng Wang
  • Leyuan Zhou
  • Zhihui Liu
  • Jiwei Zhang
  • Yuan Yin
  • Bing Gu
  • Zhaohui Huang
Original Article

Abstract

As a potential tumor suppressor, the detailed clinical application value of sorting nexin 1 (SNX1) has not been elucidated in colorectal cancer (CRC). The aim of the present study was to evaluate the expression of SNX1 in CRC tissues and to determine its correlation with clinicopathologic characteristics and its impact on patient’s prognosis. We detected the expression of SNX1 mRNA in 72 CRC patients and SNX1 protein in 237 CRC patients by real-time polymerase chain reaction (RT-PCR) and immunohistochemical staining, respectively. Relationship between the expression of SNX1 and various clinicopathological features in these patients was evaluated. Both the mRNA and protein expression of SNX1 were remarkably decreased in CRC tissues compared with paired non-cancerous tissues, and the down-regulation of SNX1 protein was strongly associated with poor differentiation and poor overall survival (OS) rate of CRC patients. Ectopic SNX1 expression repressed CRC cell growth and promoted tumor sensitivity to most commonly used chemotherapeutic drugs (oxaliplatin and 5-Fluorouracil). In conclusion, overexpression of SNX1 may serve as a new therapeutic strategy for CRC.

Keywords

Sorting nexin 1 (SNX1) Colorectal cancer (CRC) Prognosis Drug resistance 

Notes

Acknowledgments

This study was partially supported by grants from the National Natural Science Foundation of China (Nos. 81000867, 81272299, 81301920 and 81301784) and Medical Key Professionals Program of Jiangsu Province (RC2011031).

Conflicts of interest

None

References

  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Cerella C, Teiten MH, Radogna F, et al. From nature to bedside: pro-survival and cell death mechanisms as therapeutic targets in cancer treatment. Biotechnol Adv. 2014;32:1111–22.CrossRefPubMedGoogle Scholar
  3. 3.
    Nguyen LN, Holdren MS, Nguyen AP, et al. Sorting nexin 1 down-regulation promotes colon tumorigenesis. Clin Cancer Res. 2006;12:6952–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang Z, Huang S, Wang Q, et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res. 2011;71:2582–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen X, Chen S, Hang W, et al. MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. Biomed Pharmacother. 2014;68:589–95.CrossRefPubMedGoogle Scholar
  6. 6.
    Nishimura Y, Takiguchi S, Ito S, et al. EGF-stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib-resistant human lung cancer cell line. Int J Oncol. 2015;46:1721–9.PubMedGoogle Scholar
  7. 7.
    Centelles JJ. General aspects of colorectal cancer. ISRN Oncol. 2012;2012:139268.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Osman I, Bajorin DF, Sun TT, et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res. 2006;12:3374–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Gullapalli A, Wolfe BL, Griffin CT, et al. An essential role for SNX1 in lysosomal sorting of protease-activated receptor-1: evidence for retromer-, Hrs-, and Tsg101-independent functions of sorting nexins. Mol Biol Cell. 2006;17:1228–38.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Worby CA, Dixon JE. Sorting out the cellular functions of sorting nexins. Nat Rev Mol Cell Biol. 2002;3:919–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Ernst T, Score J, Deininger M, et al. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol. 2011;153:43–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Ara S, Kikuchi T, Matsumiya H, et al. Sorting nexin 5 of a new diagnostic marker of papillary thyroid carcinoma regulates Caspase-2. Cancer Sci. 2012;103:1356–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Rivera J, Megias D, Bravo J. Sorting nexin 6 interacts with breast cancer metastasis suppressor-1 and promotes transcriptional repression. J Cell Biochem. 2010;111:1464–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775–827.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013–26.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zehua Bian
    • 1
  • Yuyang Feng
    • 1
  • Yao Xue
    • 1
  • Yaling Hu
    • 1
  • Qifeng Wang
    • 2
  • Leyuan Zhou
    • 1
  • Zhihui Liu
    • 1
  • Jiwei Zhang
    • 1
  • Yuan Yin
    • 1
  • Bing Gu
    • 3
    • 4
  • Zhaohui Huang
    • 1
  1. 1.Wuxi Oncology InstituteThe Affiliated Hospital of Jiangnan UniversityWuxiChina
  2. 2.Department of PathologyFudan University Shanghai Cancer CenterShanghaiChina
  3. 3.Department of Laboratory MedicineAffiliated Hospital of Xuzhou Medical CollegeXuzhouChina
  4. 4.Medical Technology Institute of Xuzhou Medical CollegeXuzhouChina

Personalised recommendations